Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Change in Accured Expenses: 2009-2024

Historic Change in Accured Expenses for Ironwood Pharmaceuticals (IRWD) over the last 16 years, with Dec 2024 value amounting to -$20.2 million.

  • Ironwood Pharmaceuticals' Change in Accured Expenses rose 15397.10% to $10.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $767,000, marking a year-over-year increase of 102.84%. This contributed to the annual value of -$20.2 million for FY2024, which is 263.23% down from last year.
  • Per Ironwood Pharmaceuticals' latest filing, its Change in Accured Expenses stood at -$20.2 million for FY2024, which was down 263.23% from $12.4 million recorded in FY2023.
  • In the past 5 years, Ironwood Pharmaceuticals' Change in Accured Expenses ranged from a high of $12.4 million in FY2023 and a low of -$20.2 million during FY2024.
  • Its 3-year average for Change in Accured Expenses is $998,667, with a median of $10.8 million in 2022.
  • In the last 5 years, Ironwood Pharmaceuticals' Change in Accured Expenses surged by 509.38% in 2022 and then slumped by 263.23% in 2024.
  • Yearly analysis of 5 years shows Ironwood Pharmaceuticals' Change in Accured Expenses stood at -$7.5 million in 2020, then skyrocketed by 64.85% to -$2.6 million in 2021, then surged by 509.38% to $10.8 million in 2022, then grew by 14.38% to $12.4 million in 2023, then crashed by 263.23% to -$20.2 million in 2024.